This study demonstrates that TGF‐β inhibition activates AKT signaling in atrophic and hypertrophic adiposity, ameliorating adipose morphological function and systemic glucolipid metabolic disorders in aP2‐SREBP‐1c lipodystrophy mice without similar effects in ob/ob mice. This evidence concerns the gene TGFB1 and lipodystrophy.